SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical aims revenue growth of 18-20% for current fiscal

29 May 2013 Evaluate

Sun Pharmaceutical Industries, country’s third largest drug maker by sales aims revenue growth of 18-20% for the current fiscal year ending March 2014. It is planning to invest Rs 800 crore on capital expenditure and file about 25 generic drug applications for approval in the United States.

The entity’s sales rose by 31.8% in the March quarter over the year-ago period to Rs 3,071.5 crore, and its gross margin rose as material costs increased by only 7.9%. While, the profit was boosted by higher other income and lower tax rate at 13.8%.

Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×